Study entitled “Chagas disease and leishmaniasis surveillance in Antioquia”.
Archived on August 23, 2026. Solicitation posted by DEPT OF DEFENSE (DEPT OF THE NAVY) on July 24, 2026. Solicitation ERP_13013778730.
NAICS 541700 (541700). Set-aside: No Set aside used. Original response deadline: . Full description on SAM.gov.
Description
The requirement is for a 12-month base period of performance with an additional 12 month extension.
The contractor shall provide services including (but not limited to) project management, ethical and regulatory approval, collection and identification of samples and screening.
The contractor shall provide all supplies for sample collection and laboratory testing. NAMRU SOUTH will provide some reagents and supplies for collection and testing depending on funding availability.
In addition, the contractor shall provide disease incidence data available from direct sources such as active human subject studies or indirectly from local health authorities.
The study sites will be located in:
Colombia:
• Antioquia state
• Other sites as requested by NAMRU SOUTH
Monitoring activities will be conducted by NAMRU SOUTH via monthly conference calls and visits to selected field sites during the contract period. Monthly, short reports are expected during the conduction of the study.
- Performance Requirements:
The Offeror is encouraged to propose a labor mix and level of effort based on their technical approach. The contractor shall provide general classes of services including (but not limited to) project management, provision of clinical samples and biological specimens, laboratory testing, shipment of samples, data analysis and reporting.
Laboratory molecular testing shall be performed by the contractor in response to NAMRU SOUTH requirements. In addition, the contractor shall provide demographic, clinical and laboratory test results to NAMRU SOUTH.
Monitoring activities will be conducted by NAMRU SOUTH and periodical monitoring visits and reports will be coordinated. Frequent communications such as monthly teleconferences are expected during the conduction of the study.
- FIELD AND LAB ACTIVITIES
- Entomological component
-
-
- Approvals: Secure all ethical and regulatory approvals required for collecting entomological specimens in Colombia.
- Sand fly collection: Perform field collections in two different regions of Antioquia: San Luis municipality and Turbo municipality using standard methods (CDC light traps). Secure the collection of approximately 200 sand flies and store them in ethanol. Record field collection data and prepare a database.
- Triatomine collection: Perform field collections of Triatomine bugs in two different regions of Antioquia: San Luis municipality and Turbo municipality using standard methods (Angulo tramps). Secure the collection of 40-50 triatomine bugs and store them at room temperature in ethanol.
- Entomological specimen identification: Perform taxonomic identification of at least 50% of specimens collected and preserve specimens for molecular testing.
- Lab testing: Determine the status of infection with Leishmania and Trypanosoma cruzi in 80 entomological specimens using molecular methods. Provide DNA aliquots of positive specimens to NAMRU SOUTH if requested.
- Data sharing: Provide information on field site, entomological specimen numbers recorded, sand fly and triatomine species identified per collection period per site, specimen inventory, and relevant epidemiological data as requested by NAMRU SOUTH Entomology.
-
-
- Animal component
-
-
- Approvals: Secure all ethical and regulatory permits approvals for conducting work with animals and collecting specimens in Colombia.
- Fieldwork: Perform animal trapping of potential Leishmania spp. reservoirs in Province (El Barcino) located in Campamento municipality and (El Alto del Pollo) Puerto Triunfo municipality.
- Specimens: Collect a minimum of 20 specimens from potential animal reservoirs, process and preserve them for molecular testing.
- Lab testing: Determine the status of infection with Leishmania and Trypanosoma spp in twenty specimens of wild mammals using serological or molecular methods.
- Data sharing: Provide information on collection site up to the district level, clinical and other relevant epidemiological data and laboratory testing results as requested by NAMRU SOUTH Parasitology.
- Human component
-
-
-
- Approvals: Secure all ethical and regulatory permits approvals for conducting human subject research in Colombia.
- Fieldwork: Enroll human subjects from Campamento and Puerto Triunfo (Antioquia) and Puerto Boyacá (Boyacá) in Colombia. Enrolment and specimen collection should follow the criteria as defined by the governing human use protocol.
- Specimens: Collect a minimum of 100 specimens from human participants, process and preserve them for molecular testing.
- Lab testing: Determine the status of infection with Leishmania and Trypanosoma spp in 100 human specimens using serological or molecular methods.
- Data sharing: Provide information on collection sites up to the district level, clinical and other relevant epidemiological data and laboratory testing results as requested by NAMRU SOUTH Parasitology.
-
- DATA SHARING
- The contractor shall provide data collection information on field sites, entomological specimen numbers recorded, sand flies and triatomines species identified per collection period per site, specimen inventory, and relevant epidemiological data as requested by NAMRU SOUTH Entomology.
- The contractor shall provide information on enrollment site up to the district level and if possible, up to the household level, clinical symptoms and other relevant epidemiological data as requested by NAMRU SOUTH Parasitology.
- At the completion of a study or when requested, the contractor shall provide all data to NAMRU SOUTH.
- The contractor shall provide laboratory testing data as requested by NAMRU SOUTH Parasitology and Entomology.
- Provide input for report, scientific manuscripts and thesis preparation and participate on authorship of resulting products.
- EQUIPMENT, SUPPLIES AND MATERIALS
- The contractor will cover the cost of supplies and materials necessary for sample collection, transport, storage and screening.
- Depending on funding availability, NAMRU SOUTH may provide DNA extraction kits, PCR primers and master mix for up to 200 subjects per performance period.
- The contractor shall provide all required equipment. No Government Furnished equipment will be provided.
- SHIPMENTS
- The contractor shall cover the cost of one shipment of samples per year to NAMRU SOUTH Lima facilities per year upon coordination with the Department of Parasitology.
The delivery address is:
Parasitology – NAMRU SOUTH
Av. Venezuela cd 36 S/N – Bellavista – Callao
- The Contractor shall include the following into the shipments of samples:
- Clinical samples collected as part of the study.
- Nucleic acid material (if applicable) obtained from collected samples covered under this contract.
- Spreadsheet with study codes, type of sample and volume.
- DELIVERABLES
- Once fieldwork starts, the contractor shall provide reports indicating the number of participants enrolled, age, gender and malaria screening results on a monthly basis or as requested by NAMRU SOUTH.
- A minimum of 200 sand flies and 40 triatomine bugs collected and identified morphologically. A minimum of 80 entomological specimens tested for Leishmania and Trypanosoma cruzi.
- At the completion of the study or when requested, the contractor shall provide the study database to NAMRU SOUTH. Information collected should include geographical data up to the household level, clinical symptoms, relevant epidemiological data and laboratory results.
- SPECIAL REQUIREMENTS: N/A
- TASK ORDERS: N/A
- ANNUAL SCHEDULE
Quarter 1 and 2:
- Organizational meetings, identify VBD transmission sites focusing on Chagas and leishmania infections through meetings with key contacts and MoH personnel.
- Obtain project and IRB permits and coordinate collection activities with local authorities.
- Purchase supplies and materials for field work and laboratory activities.
- Participate in bimonthly teleconferences with NAMRU SOUTH.
- Conduct human sample collection activities in Chagas and Leishmaniasis endemic areas in Antioquia, Colombia. Database preparation and submission to NAMRU SOUTH.
- Send demography, clinical data and laboratory results to NAMRU SOUTH.
Quarter 3 and 4:
- Continue human, reservoir, and entomological collection activities in leishmaniasis and Chagas disease endemic areas in Colombia . Database preparation and submission to NAMRU SOUTH.
- Perform molecular testing of entomological specimens for Leishmania spp. and T. cruzi infection.
- Send demography, clinical data and laboratory results to NAMRU SOUTH.
- Database quality control and data analysis.
- Participate in bimonthly teleconference with NAMRU SOUTH.
- Perform one shipment of human samples to NAMRU SOUTH Lima.
- Assist NAMRU SOUTH with data analysis, revision of study results and reporting, and manuscript preparation.
Period of performance:
The project is scheduled to be conducted in 12 months.
TASK/
DELIVERABLE
PERFORMANCE STANDARD
PERFORMANCE INDICATOR/
ACCEPTABLE LEVEL OF PERFORMANCE (ALP)
METHOD OF SURVEILLANCE
AND RISK RELATED SCHEDULE
PERFORMANCE RATING
Compliance of products, services, documents, related deliverables, and overall quality of work performance.
Contract requirements met with few minor and no significant problems encountered.
Performance meets all technical and functional requirements in the PWS, and contains pertinent, useful, and informative data and information.
Contractor’s technical performance meets all contract requirements.
Problems that are encountered are minor in nature, and are as follows:
- does not cause a delay in schedule;
- does not cause costs to increase;
- involves minimal effort to fix; and
- does not affect overall contractor performance
All matters shall be resolved in a satisfactory and timely manner.
100% Inspection
Are study reports complete and are they compliant with various Government regulations?
Assignment of performance rating and criteria:
Excellent: Performance meets and exceeds contract requirements. Performance delivered with no required re-performance /rework; problems encountered were minor and resolved in a highly effective manner, having no impact on schedule, costs, and overall contractor performance.
Acceptable: Performance meets most contract requirements. Performance delivered with minimal re-performance/rework; problems encountered were minor and resolved in a satisfactory manner.
Unacceptable: Performance fails to meet many contract requirements. Substantial problems were encountered and were resolved in a less than satisfactory manner causing significant impact to schedule, cost, and/or overall contractor performance. Significant re-performance or rework required.
Timeliness of
Performance and
Services and Product
Deliverables, including
Administrative aspects
of Performance.
Contract requirements
met with few minor and
no significant problems
encountered.
Performance meets all
technical and functional
requirements in the PWS, and provides on time pertinent, useful, and informative data and information.
Contractor’s technical
performance meets all
contract requirements.
Problems that are
encountered are minor
in nature, and are as follows:
- does not cause a delay in schedule;
- does not cause costs to increase;
- involves minimal effort to fix; and
- does not affect overall contractor performance
All matters shall be resolved in a satisfactory and timely manner.
100% Inspection
Is the contractor meeting established timeframes?
Assignment of performance rating and criteria:
Excellent: Performance meets all contract
timeliness requirements. Problems that
are encountered are minor and resolved in
a highly effective manner, having no
impact on schedule, cost, and overall
contractor performance.
Acceptable: Performance meets most
timeliness requirements. Performance
delivered with minimal reperformance/
rework; problems encountered were minor and resolved in a satisfactory manner. Minimal impact on schedule, cost, and overall contractor performance
Unacceptable: Performance fails to meet
many timeliness requirements. Substantial
problems were encountered and were resolved in a less than satisfactory manner causing significant impact to schedule,cost, and/or overall contractor performance.
Commitment to Customer Satisfaction and Business-like concern for its Customers’ interest including responsiveness to internal and external Governments.
Contract requirements met with few minor and no significant problems encountered.
Performance meets all technical and functional requirements in the PWS, and contains pertinent, useful, and informative data and information.
Contractor’s technical performance meets all contract requirements. Problems that are encountered are minor in nature, and are as follows:
- does not cause a delay in schedule;
- does not cause costs to increase;
- involves minimal effort to fix; and
- does not affect overall contractor performance
All matters shall be resolved in a satisfactory and timely manner.
100% Inspection
Is the contractor committed to high customer satisfaction? How proactive is the contractor? Is the contractor providing positive value to the Government?
Has the contractor communicated in a timely manner unexpected delays or issues and proposed alternative solutions to meet governments contract requirements?
Assignment of performance rating and criteria:
Excellent: Performance meets and exceeds contract requirements. Performance delivered with no required re-performance /rework; problems encountered were minor and resolved in a highly effective manner, having no impact on schedule, costs, and overall contractor performance.
Acceptable: Performance meets most contract requirements. Performance delivered with minimal re-performance/rework; problems encountered were minor and resolved in a satisfactory manner. Minimal impact on schedule, cost, and overall contractor performance.
Unacceptable: Performance fails to meet many contract requirements. Substantial problems were encountered and were resolved in a less than satisfactory manner causing significant impact to schedule, cost, and/or overall contractor performance. Significant re-performance or rework required.
Overall Satisfaction
Contract requirements met with few minor and no significant problems encountered.
Performance meets all technical and functional requirements in the PWS, and contains pertinent, useful, and informative data and information.
Contractor’s technical performance meets all contract requirements. Problems that are encountered are minor in nature, and are as follows:
- does not cause a delay in schedule;
- does not cause costs to increase;
- involves minimal effort to fix; and
- does not affect overall contractor performance
All matters shall be resolved in a satisfactory and timely manner.
Periodic Inspection
What is the Governments overall satisfaction with the contractor?
Assignment of performance rating and criteria:
Excellent: Performance meets and exceeds contract requirements. Performance delivered with no required re-performance /rework; problems encountered were minor and resolved in a highly effective manner, having no impact on schedule, costs, and overall contractor performance.
Acceptable: Performance meets most contract requirements. Performance delivered with minimal re-performance/rework; problems encountered were minor and resolved in a satisfactory manner. Minimal impact on schedule, cost, and overall contractor performance.
Unacceptable: Performance fails to meet many contract requirements. Substantial problems were encountered and were resolved in a less than satisfactory manner causing significant impact to schedule, cost, and/or overall contractor performance. Significant re-performance or rework required.
Overview
Award Overview
Possible prior contracts
Sign in to see possible prior contracts for this requirement (matched by agency, NAICS and place of performance; not confirmed).
Contacts
Contracting Officer
Primary Contact
Documents
No documents available.
Lifecycle
ERP_13013778730- Solicitation
Award typically follows within 30–90 days after the response deadline. (estimate)
- 2×SolicitationCurrentJul 17, 2026
Study entitled “Chagas disease and leishmaniasis surveillance in Antioquia”.
Similar Opportunities
Title | Phase | Agency | NAICS | Set Aside | Posted | Deadline | Location |
|---|---|---|---|---|---|---|---|
NOTICE: ALL INFORMATION PRESENTED IS CONSIDERED DRAFT AND NOT FINAL UNTIL THE RELEASE OF THE FINAL SOLICITATION. THIS IS FOR INFORMATIONAL PURPOSES TO AID INDUSTRY IN UNDERSTANDING THE INTENT OF THE GOVERNMENT WITH REGARDS TO THE ANTICIPATED PROCUREMENT. The notification shares the questions submitted by industry and the corresponding Government responses regarding the DRAFT Performance Work Statement (PWS) for the anticipated procurement related to NAWCAD Battlespace Modeling and Simulation Engineering Services Notification of Intent/Sources Sought Notice ID: N00421-25-RFPREQ-54000MA-0059. The Government encourages the submission of constructive feedback on the anticipated procurement from all potential Offerors, including those interested in subcontracting opportunities, to Contract Specialist, Karen Joachim, at karen.v.joachim.civ@us.navy.mil. The Government appreciates industry engagement and will take all suggestions under advisement. | Special Notice | 541715 | No Set-Aside | 04/14/2026 | 04/28/2026 | St James, MD | |
INTRODUCTION: The National Institute of Allergy and Infectious Diseases (NIAID), one of 27 institutes of the NIH, an agency within the Department of Health and Human Services (DHHS); conducts and supports research to understand, treat, and ultimately prevent the myriad infectious, immunologic, and allergic diseases that threaten the health and longevity of human lives.Through a variety of research grants and contracts, NIAID’s Division of Microbiology and Infectious Diseases (DMID) specifically supports extramural research to develop new medical interventions against infectious disease threats to include drug-resistant pathogens. NIAID/DMID intends to use this BAA to help address goals articulated in a number of strategic plans, such as in the Public Health Emergency Medical Countermeasures Enterprise Strategy and Implementation Plan (https://aspr.hhs.gov/PHEMCE/2024-PHEMCE-SIP/Pages/default.aspx), as well as current prioritized antimicrobial resistant threats identified by national death and infection estimates as determined by the Centers for Disease Control and Prevention’s (CDC) to prevent and control antimicrobial resistance (https://www.cdc.gov/antimicrobial-resistance/data-research/threats/index.html). In addition, NIAID/DMID intends to use this BAA to encourage projects that align with the NIH priorities of enhancing rigor & reproducibility, improving biosafety and biosecurity, and the use of complementary non-animal testing methods where appropriate. This Broad Agency Announcement (BAA) is soliciting proposals to advance the research and development of promising candidate therapeutics, vaccines, and diagnostics for infectious diseases in each of three (3) Research Areas described below and more thoroughly discussed in the attached BAA Solicitation. An offeror should carefully review the content of the BAA Solicitation No. HHS-NIH-NIAID-BAA2026-1 for the comprehensive information regarding all requirements, the technical objective of each Research Area of this BAA Solicitation, instructions regarding the proposal submission, and a description of the evaluation and award process. Please note, due to the competitive nature of the BAA Solicitation, the NIAID is unable to offer advice or feedback regarding an offeror’s specific technical approach. Offerors should exercise their professional judgment when compiling their proposals in line with the requirements and specifications of the BAA Solicitation. Research Area 001 - Vaccine Candidates: The objective is to develop vaccine candidates through an early phase clinical trial that use a needle free (i.e., alternative to classical needle and syringe, see below for description) route of delivery to protect against infections caused by viral pathogens that include but are not limited to respiratory and vector borne viruses. The scope of this vaccine research area includes the preclinical development of a needle free vaccine candidate, IND enabling studies, limited process development, Good Manufacturing Practice (GMP) compliant manufacturing, regulatory submissions to the U.S. Food and Drug Administration (FDA) and conduct of a Phase 1 or early Phase 2 clinical trial. The scope of work must include a clinical trial. Offerors must propose a single vaccine candidate for protection against a specific viral pathogen. The vaccine candidate may provide a breadth of protection against other viral strains or viruses. A strong justification is required to support (1) the proposed vaccine antigen and platform for the disease indication, (2) the use of a clinically relevant adjuvant (if needed), and (3) a clinically relevant needle free route of delivery. Research Area 002 - Therapeutic Candidates: The objective is to develop safe, effective, new therapeutic products that will improve patient outcomes against serious infectious diseases for which there are no approved therapeutics, or for those that are refractory to treatment despite appropriate antimicrobial therapy or due to pathogen resistance. Infectious diseases caused by the following viruses, bacteria and fungi pathogens are targeted: Viral hemorrhagic fever viruses (e.g., EBOV, SUDV, MARV, LASV, hantavirus) https://www.cdc.gov/viral-hemorrhagic-fevers/about/index.html Encephalitic paramyxoviruses (e.g. hendra virus, nipah virus) Picornaviruses (broad spectrum approaches that include EV68, EV70 and coxsackie virus) At least two of the following (i.e., addressed with a broad spectrum antimicrobial): susceptible and carbapenem-resistant Enterobacteriaceae (CRE), susceptible and multidrug resistant (MDR) Pseudomonas aeruginosa, and susceptible and Carbapenem-resistant Acinetobacter (CRAB), with potential to improve patient outcomes in the clinic; Candida auris, Cryptococcus spp., Aspergillus fumigatus, and/or Mucorales Adjunct medical interventions to support or enhance effectiveness of antimicrobial agents to address underlying pathology that is not resolved after clearance of pathogens, may be considered. Important notice to Offerors: For this Research Area, “therapeutic” activity means curing disease by eliminating or substantially reducing infective pathogens by administering antimicrobial pharmaceutical agents, with or without a host-directed therapy. Additionally, proposed therapeutic products should consider the impact on a healthy microbiome. Preventative treatments are not included in the scope of this Research Area. A therapeutic candidate refers to an advanced lead series, preclinical candidates, or a clinical candidate, that is a new chemical entity. This includes small molecules, natural products, nucleosides, or peptides of </= 40 amino acids, monoclonal antibodies, nanobodies, nanobody conjugate/fusion products, microbiome-based therapeutics or bacteriophages. Research Area 002 will support lead optimization, pre-clinical Investigational New Drug (IND) enabling studies, and Phase 1 clinical trials (or proof of concept Phase 2 clinical trials) of lead candidates with demonstrated therapeutic activities. This includes support for traditional, novel (e.g., small molecules) and non-traditional (e.g., including but not limited to phage, and host-directed) therapeutics for infectious diseases where patients lack effective interventions, as well as therapeutics that promote host-mediated resolution of disease. The scope of support differs depending on the developmental stage of the project being proposed, which is further discussed in the BAA Solicitation. Research Area 003 - In Vitro Diagnostics The objective of Research Area 003 is to develop innovative, technology platforms that will speed detection and identification of infectious viruses covering a broad panel of virus families, including viruses causing acute infections as well as those causing chronic infections. Technology platform innovation to achieve faster actionable sequencing results (approaching 2 hr) direct from primary clinical specimens, as well as more accessible workflow and configuration (i.e., point-of-care) are preferred. Furthermore, full sample-to-answer platform solutions are preferred. The system should accept specimen volumes from 0.5 to 5 milliliters (mL). The system should include nearly full automation (little or no hands-on activity after specimen has been loaded into system). Sample preparation components of the system should yield sufficient analyte recovery from a starting titer of 10-100 genomic copies per mL of biofluid for downstream analysis, including detection, identification, and characterization of the nucleic acid material. Innovations during platform development might include, for example: Automated sample prep for high recovery from low pathogen load. Faster specimen-to-answer for total test time <2 hours. Broad viral pathogen detection capability, covering one or more members of the priority pathogen families (see below). Targeted, or even untargeted pathogen detection and identification via long-read sequencing or other detection methods. Multiple specimen throughput per run for reduced cost. Analytical sensitivity approaching 5-50 genome copies per mL of starting biofluid. Assay reconfigurability to respond rapidly to a novel pathogen in days or weeks rather than months (i.e., agnostic diagnostic solution). Priority Pathogens The diagnostic test system must detect analytes from at least one, and preferably several, of the following agents and markers: Arenaviridae (e.g., Lassa virus) Phenuviridae (e.g., Rift Valley fever virus) Peribunyayviridae (e.g., Oropouche virus) Hantaviridae (e.g., Hantavirus) Nairoviridae (e.g., Crimean Congo Hemorrhagic fever virus) Filoviridae (e.g., Sudan virus, Ebola virus, Marburg virus) Flaviviridae (e.g., Hepatitis C virus, West Nile Virus) Paramyxoviridae (e.g., Nipah virus) Togaviridae (e.g., Chikungunya virus) Picornaviridae (e.g., Enterovirus) PROPOSAL SUBMISSION: Proposals Due Date and Time – December 8, 2026, 3:00 PM Eastern Time For this solicitation, the NIAID requires proposals to be submitted online via the NIAID electronic Contract Proposal Submission (eCPS) website. Submission of proposals by any other method is not permitted. For directions on using eCPS, go to the website: https://ecps.nih.gov and thenclick on "How to Submit." | Solicitation | 541715 | No Set-Aside | 10/09/2026 | 12/08/2026 | - | |
This BAA is intended to solicit extramural research and development ideas using the authority provided by United States Code, Title 10, Section 4001. This BAA is issued under the provisions of the Competition in Contracting Act of 1984 (Public Law 98-369), as implemented in Federal Acquisition Regulation 6.102(d) (2) and 35.016. In accordance with FAR 6.102, projects funded under this BAA must be for basic and applied research to support scientific study and experimentation directed toward advancing the state-of-the-art or increasing knowledge or understanding rather than focusing on development of a specific system or hardware solution. Research and development funding through this BAA are intended and expected to benefit and inform both military and civilian medical practice and knowledge. This BAA provides a general description of USSOCOM's research and development programs, including research areas of interest, evaluation and selection criteria, pre-proposal/pre-application and full proposal/application preparation instructions, and general administrative information. Submission of a pre-proposal is required. After review, if the USSOCOM is interested in receiving a full proposal, the Offeror will be invited to submit a full proposal or full application. Specific submission information and additional administrative requirements can be found in the document titled "General Submission Instructions" available in Grants.gov along with this BAA The BAA is continuously open for a 5-year period, from 01 August 2023 through 31 July 2028, at 11:59 p.m. Eastern Time. Submission of a pre-proposal is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) (https://eBRAP.org/). Preproposals may be submitted at any time throughout the 5-year period. If the USSOCOM is interested in receiving a full proposal/application, the Principal Investigator will be sent an invitation to submit via eBRAP. A full proposal/application must be submitted through Grants.gov (http://www.grants.gov/). Invited full proposals/applications can be submitted under this BAA through 31 July 2028. The BAA with revised research areas of interests, and General Submission Instructions is available for download on Grants.gov. Search opportunity number HT9425-23-S-SOC1. | Special Notice | 541720 | No Set-Aside | 07/29/2026 | 07/31/2028 | - | |
This BAA is intended to solicit extramural research and development ideas using the authority provided by United States Code, Title 10, Section 4001. This BAA is issued under the provisions of the Competition in Contracting Act of 1984 (Public Law 98-369), as implemented in Federal Acquisition Regulation 6.102(d) (2) and 35.016. In accordance with FAR 6.102, projects funded under this BAA must be for basic and applied research to support scientific study and experimentation directed toward advancing the state-of-the-art or increasing knowledge or understanding rather than focusing on development of a specific system or hardware solution. Research and development funding through this BAA are intended and expected to benefit and inform both military and civilian medical practice and knowledge. This BAA provides a general description of USSOCOM's research and development programs, including research areas of interest, evaluation and selection criteria, pre-proposal/pre-application and full proposal/application preparation instructions, and general administrative information. Submission of a pre-proposal is required. After review, if the USSOCOM is interested in receiving a full proposal, the Offeror will be invited to submit a full proposal or full application. Specific submission information and additional administrative requirements can be found in the document titled "General Submission Instructions" available in Grants.gov along with this BAA The BAA is continuously open for a 5-year period, from 01 August 2023 through 31 July 2028, at 11:59 p.m. Eastern Time. Submission of a pre-proposal is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) (https://eBRAP.org/). Preproposals may be submitted at any time throughout the 5-year period. If the USSOCOM is interested in receiving a full proposal/application, the Principal Investigator will be sent an invitation to submit via eBRAP. A full proposal/application must be submitted through Grants.gov (http://www.grants.gov/). Invited full proposals/applications can be submitted under this BAA through 31 July 2028. The BAA with revised research areas of interests, and General Submission Instructions is available for download on Grants.gov. Search opportunity number HT9425-23-S-SOC1. | Special Notice | 541720 | No Set-Aside | 07/23/2025 | 07/31/2028 | - | |
The primary objective of this work under Solicitation Number N3943026R5001 is to establish a scientifically sound methodology to quantify and evaluate per- and polyfluoroalkyl substances (PFAS) distributions in precipitation, ambient fog water, and ambient soils at multiple active U.S. Navy installations. Ultimately, this study aims to assess how atmospheric deposition (via rain and fog) contributes to PFAS concentrations found in surface soils, and to determine the ideal sample sizes needed to calculate reliable background threshold values (BTVs) for future Navy-wide environmental investigations. | Awarded | 541700 | No Set-Aside | 10/02/2026 | Open | Port Hueneme, CA |
Additional Details
Solicitation Number
ERP_13013778730
Archive Date
Aug 23, 2026
Office Address
SILVER SPRING, MD, 20910-7500